Itonis, Inc. Announces Its Emesyl Anti-Nausea Product is Again Available for Purchase via Amazon.com

LAGUNA HILLS, CA--(Marketwired - September 27, 2016) - Itonis, Inc. (OTC PINK: ITNS) is pleased to announce that its Emesyl^® anti-nausea homeopathic product is again available for purchase via Amazon.com.

Emesyl^® is listed for sale in Amazon's Health, Household & Personal Care category.

The product is also being fulfilled by Amazon and can be found for purchase here: https://www.amazon.com/Itonis-Pharmaceuticals-Emesyl-Nausea-Relief/dp/B00U20H3KI/ref=sr_1_1_a_it?ie=UTF8&qid=1474906172&sr=8-1&keywords=emesyl

"We're pleased to be able to offer Emesyl^® for sale on Amazon again. This provides Itonis with a greater exposure to build our brand, and it offers consumers another sales channel to purchase our anti-nausea homeopathic product," said Steve Pidliskey, Itonis Vice President.

About Itonis, Inc.

Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyECheck's patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.

Safe Harbor:

Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.